A recent analysis from Deloitte Recap LLC showed that, when it comes to advancing a product from Phase I to approval, the odds are significantly better for biotechs who have a big pharma or big biotech partner. Read More
Correctly predicting the future is a necessary but difficult task for biotech executives. Making accurate forecasts about demographic trends, clinical data, regulatory decisions, competition, and prescription trends can guide where to allocate limited capital and even the timing on when to raise more. Read More
